Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Advaxis, Inc. (ADXS) Cancer Drug Suggests Potential Of Immunotherapy 0 comments
    May 13, 2013 2:48 PM | about stocks: ADXS

    Immunotherapy, the enlisting of the body's own immune system to more efficiently attack cancer and other diseases, has become a major point of attention all over the world as a dramatic new approach to disease treatment. It's a science that is still developing, with a growing pipeline of new immunotherapy drugs just now undergoing initial trials, but the potential is immense. Instead of blasting cancer patients with a cocktail of poisons and radiation, hurting good cells as well as bad, immunotherapy offers the hope of focusing more energy much more accurately and efficiently. The result could be a day when a whole range of cancers can be treated effectively and rapidly, with almost no negative side effects.

    An example is Advaxis, a New Jersey based biotech company that is helping to lead the immunotherapy charge with a number of developing drug candidates. One of their prospects, ADXS-HPV, for use with women suffering from recurrent/refractory cervical cancer who have not had success with traditional cytotoxic therapy. The drug has been undergoing the final part of a Phase II study, and recently updated results have been extremely encouraging.

    From a safety standpoint, the drug continues to be well-tolerated, a strong point of the immunotherapy approach. Similar patients undergoing chemotherapy, by comparison, virtually all have fairly severe adverse effects. In addition, the drug is showing significant efficacy in early results, with major improvements in initial survival rates. Although the final results still have to be reported, ADXS-HPV appears to be an effective weapon against cervical cancer, without the toxicity and dangerous side effects of traditional chemotherapy. With the next update due in June of 2013, a partnership of some sort is not out of the question.

    For more information visit advaxis.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.